Actively Recruiting
Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia
Led by Assiut University · Updated on 2026-04-30
100
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized controlled trial aims to compare the efficacy and safety of high-velocity nasal insufflation (HVNI) versus standard noninvasive ventilation (NIV) in adult patients experiencing acute exacerbations of community-acquired pneumonia (CAP) accompanied by hypoxemic respiratory failure. The primary focus is on assessing treatment failure within 48 hours, defined as the need for intubation or death. Secondary outcomes include evaluations of gas exchange parameters, patient comfort levels, duration of ICU stay, and 28-day mortality rates.
CONDITIONS
Official Title
Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �318 years
- Clinical and radiographic diagnosis of community-acquired pneumonia
- Respiratory failure with PaO2/FiO2 ratio �3300 mmHg or respiratory rate �325 breaths per minute
- Informed consent obtained
You will not qualify if you...
- Hemodynamic instability requiring vasopressors
- Altered mental status with Glasgow Coma Scale score less than 13
- Contraindications to NIV or HVNI such as facial trauma or recent upper airway surgery
- Presence of a Do-Not-Intubate (DNI) order
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Assuit University
Asyut, Assuit, Egypt, 71515
Actively Recruiting
Research Team
A
Ahmad M. Shaddad, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here